Efficacy of Matrifen in Patients Older Than 18 Years With Severe, Chronic Pain

Nycomed3,000 enrolled

Overview

The aim of the study is to evaluate the efficacy and safety of matrifen in patients with severe and chronic pain who can only be sufficiently treated with opioid analgesics (WHO class 3).

Study Type

OBSERVATIONAL

Enrollment

3,000

Conditions

Severe, Chronic Pain

Interventions

MatrifenDRUG

as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.2)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Main inclusion criteria: * Patients with severe, chronic pain Main exclusion criteria: * Hypersensitivity of fentanyl * Co-administration of monoaminooxidase-inhibitors * Pregnancy * Respiratory depression * Chronic obstructive pulmonary disease (COPD) * Drug abuse * Impairment of CNS functions * Other criteria as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.3)

Locations (815)

Outcomes

Primary Outcomes

Treatment success, efficacy of Matrifen

Time frame: within 1 month

Secondary Outcomes

Safety and tolerability of fentanyl and the transdermal system, quality of life

Time frame: within 1 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

"Nycomed Deutschland GmbH"

Aachen, Germany

"Nycomed Deutschland GmbH"

Aalen, Germany

"Nycomed Deutschland GmbH"

Achim, Germany

"Nycomed Deutschland GmbH"

Ahaus, Germany

"Nycomed Deutschland GmbH"

Ahlen, Germany

"Nycomed Deutschland GmbH"

Aicha, Germany

"Nycomed Deutschland GmbH"

Albstadt, Germany

"Nycomed Deutschland GmbH"

Albstadt, Germany

"Nycomed Deutschland GmbH"

Alfeld, Germany

"Nycomed Deutschland GmbH"

Alfhausen, Germany

...and 805 more locations